Vocabria 400 mg prolonged-release suspension for injection

A Phase IIIb, multi-center, non-randomized, parallel-group, open-label, hybrid type I study evaluating the efficacy, safety, implementation effectiveness, and patient-reported outcomes of oral dolutegravir/lamivudine once-daily as a first-line regimen followed by participant-determined optional switch to long-acting intramuscular cabotegravir plus rilpivirine every two months for the maintenance of virologic suppression in antiretroviral therapy naive adults living with HIV-1.

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)